Key Points
- Nurix Therapeutics jumped up nearly $5 a share on Wednesday.
- The company just released data from a phase 1a trial for its lead BTK inhibitor therapy.
- The company does not yet have any marketed drugs.
Nurix Therapeutics stock soared more than 21% on Wednesday. The stock, which closed at $28.96 on Tuesday, opened at $31.25 and rose as high as $36.24 in mid-day training. The stock’s 52-week high is $52.38, and its low is $21.53.
So what
The biopharmaceutical company released initial phase 1a data regarding NX-2127, its therapy for patients with relapsed or refractory B-cell cancers. According to Nurix, the drug was able to significantly reduce Bruton’s tyrosine kinase (BTK) in all of the patients in the trial. BTK is an enzyme that is a key part of the B-cell receptor-signaling pathways. By blocking the enzyme, certain B-cell leukemias and lymphomas will not be able to grow and survive.
BTK inhibitors have been shown to be effective against chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and other B-cell malignancies. Final approval for NX-2127 will depend on its safety and continued efficacy as the trials continue.
Now what
This is certainly a big deal for Nurix, which has other drugs in its pipeline, including immune-oncology drugs and adoptive cell therapies. However, none of these are past the preclinical stage. The company’s only revenue in the third quarter was from collaboration revenue, which was not enough to put the company in the black. In the third quarter, it reported revenue of $10.3 million, while the company posted a net loss of $28.8 million. With cash reserves of $465.4 million, the company is in good shape to last three years of cash burn until NX-2127 or any of its other pipeline drugs can come to market.
Nurix is facing potential competition from other pharmaceutical companies. There are three BTK inhibitors on the market, all of which are known to have significant side effects: ibrutinib, acalabrutinib and zanubrutinib. But according to a July article in the International Journal of Molecular Sciences, there are more than two dozen other BTK inhibitors that are being tested.
Should you invest $1,000 in Nurix Therapeutics, Inc. right now?
Before you consider Nurix Therapeutics, Inc., you’ll want to hear this.
Our award-winning analyst team just revealed what they believe are the 10 best stocks for investors to buy right now… and Nurix Therapeutics, Inc. wasn’t one of them.
The online investing service they’ve run for nearly two decades, Motley Fool Stock Advisor, has beaten the stock market by over 4X.* And right now, they think there are 10 stocks that are better buys.
